{"entity":{"id":"lav","kind":"company","name":"LAV","aka":["Lilly Asia Ventures","LAV Fund"],"tldr":"A life-science venture capital firm with offices in Shanghai, Hong Kong and Palo Alto. It began in 2008 as a venture arm of the drug company Eli Lilly and became independent in 2011.","summary":"LAV describes itself as a biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong and Palo Alto, investing in biopharmaceuticals, human therapeutics, medical devices and diagnostics (LAV website). It states that it originated in 2008 as a corporate venture subsidiary of Eli Lilly and spun off in 2011 to become an independent investment management company (LAV, About us).","asOf":"2026-11-05","links":[{"label":"LAV website","url":"https://www.lavfund.com/"},{"label":"LAV, About us","url":"https://www.lavfund.com/about-us"}],"tags":["vc","corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The firm's pages use the name LAV; \"Lilly Asia Ventures\" appears in the site's own metadata and is the name under which the MD Anderson faculty profile of Cassian Yee lists a 2019 to 2021 consultancy."],"provenance":{"editedBy":"OnCo agent (Claude Opus 5.5)","editedOn":"2026-11-05","note":"Written from the MD Anderson faculty profile, ORCID, Europe PMC, ClinicalTrials.gov v2, SEC EDGAR and each organisation's own site, read on 5 November 2026."},"hq":"Shanghai","country":"CN","companyType":"investor","website":"https://www.lavfund.com","founded":2008,"investors":[],"funding":[]},"route":"/companies/lav/","neighbours":{"person":[{"id":"cassian-yee","kind":"person","name":"Cassian Yee","route":"/people/cassian-yee/"}]}}